3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Dermatologic
4
Breast
4
Lymphoid
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
CNS
1
Conditions
Peritoneal Neoplasms
1
Interventions
Paclitaxel
108
Carboplatin
97
pembrolizumab
64
Cisplatin
63
Cyclophosphamide
45
Bevacizumab
35
Taxes
31
Gemcitabine
28
liposomal doxorubicin
27
Topotecan
26
fludarabine
25
olaparib
22
Nivolumab
20
Docetaxel
20
Radiotherapy
18
Brachytherapy
17
veliparib
16
Magnetic Resonance Spectroscopy
16
Doxorubicin
16
Biopsy
15
Radiation
14
niraparib
13
aldesleukin
13
Specimen Handling
13
Platinum
13
Oxaliplatin
13
Filgrastim
13
Albumin-Bound Paclitaxel
12
atezolizumab
11
Interleukin-2
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
talimogene laherparepvec
×
Gynecologic
×
Clear all
NCT03663712
2024-11-20
TEMPO
Duke University
Phase 1
Completed
28 enrolled
10 charts